BioWa, Inc. has announced that it licensed to Genentech, Inc. its POTELLIGENT™ technology for use in researching and developing select Genentech antibodies for potential therapeutic applications that may include enhancement of antibody-dependent cellular cytotoxicity (ADCC).
"Genentech is an unparalleled market leader in the field of antibody therapeutics," said Dr. Nobuo Hanai, BioWa President and CEO.
"We believe this is an important opportunity to aid the development of more effective targeted treatments for cancer and other life-threatening and debilitating diseases."
Under the terms of the agreement, BioWa will provide Genentech with exclusive commercial rights to use the technology for multiple antibodies.
In return, BioWa will receive technology access fees, and may receive milestone payments and royalties in the event that products are developed by Genentech. Additional terms were not disclosed.